title: A general assessment of the safety of HMG CoA reductase inhibitors (statins).
abstract: Few principles in medicine today are as well accepted as the benefits of using statins to reduce cardiovascular risk factors and to prevent cardiovascular disease. The recent withdrawal of a statin (cerivastatin) has lead to a re-examination of all statins, and an attempt to better assess the risk-benefit ratio of this class of drugs. Although the benefits of statin treatment are well known from a myriad of clinical trials, the safety of these compounds has not been an issue since lovastatin was first introduced in 1987. This report provides a brief review of statin safety, and reiterates the excellent profile of this class of drugs.
authors.affiliation: Medical Research Laboratories International, 2 Tesseneer Avenue, Highland Heights, KY 41076, USA. Don.Black@Mrlinternational.com
authors.forename: Donald M
authors.initials: DM
authors.lastname: Black
mesh_terms: D002986:Clinical Trials as Topic; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000188:drug therapy*; D012449:Safety
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors